Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00113347 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Erlotinib
DRUG: Docetaxel
RADIATION: Radiation Therapy

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]